Product Images Gabapentin

This appears to be a formula for calculating creatinine clearance (CLOr) in patients based on their age, weight, and serum creatinine levels. The formula is adjusted for female patients by multiplying the result by 0.85.*

This is a chart showing the mean pain score during a 4-week fixed dose period, marked as "Baseline 1 2 3 4 5 s 7". The treatment options being compared are "o-Placebo," "Gabapentin, 1800 mg/day," and "Gabapentin, 2400 mg/day."*

This text represents the results of a study on pain relief medication for PHN (post-herpetic neuralgia). Figure 3 shows the percentage of patients who experienced more than 50% pain reduction as a result of using the medication at the end of the study. The results are shown for two controlled studies (Study 1 and Study 2), and the percentage of responders is different for each study. The study compares the effects of medication to a placebo control group represented by the abbreviation "PBO" (a group of patients who did not receive the medication). The data also indicates the cost of the medication (GBP 3600) and placebo (GBP 1800) used in the study.*

This text appears to be a label of a medication, containing information about the manufacturer, dosage, and storage instructions. It is a comparison between the medication labeled "Neurontin 800mg Tablet" and another medication, packaged by "Bryant Ranck Prepack". The label also includes information about the expiration date, NDC number, and storage temperature. The medication should be kept out of reach of children.*